Regulators of the RAS-ERK pathway as therapeutic targets in thyroid cancer
Miguel A. Zaballos(Consejo Superior de Investigaciones Científicas), Pilar Santisteban(Instituto de Investigaciones Biomédicas Sols-Morreale)
Cited by 38
Related Papers
The oncogene BRAFV600E is associated with a high risk of recurrence and less differentiated papillary thyroid carcinoma due to the impairment of Na+/I− targeting to the membrane
|Endocrine Related Cancer|2006|367
ADAR1-mediated RNA editing is a novel oncogenic process in thyroid cancer and regulates miR-200 activity
|Oncogene|2020|130
An ADAR1-dependent RNA editing event in the cyclin-dependent kinase CDK13 promotes thyroid cancer hallmarks
|Molecular Cancer|2021|63
ß-catenin signaling is required for RAS-driven thyroid cancer through PI3K activation
|Oncotarget|2016|53
FOXE1 regulates migration and invasion in thyroid cancer cells and targets ZEB1
|Endocrine Related Cancer|2020|43